New Report Foresees Increased Biopharma RFP Volume and Shift to Large CROs

Share Article

Life Science Strategy Group Launches New Report: Biopharmaceutical RFP Flow, Characteristics and Outlook

Life Science Strategy Group, LLC is pleased to announce the launch of its new report: Biopharmaceutical RFP Flow, Characteristics and Outlook. Takeaways from over 133 outsourcing decision makers and members of the OutsourcePharma Advisory Board indicate that mid-size and large sponsors foresee increases in RFP volume for outsourced services across all phases through December 2014.

The report finds sponsors are generally satisfied with existing vendors, but some are actively considering switching to larger, more global CROs which include Quintiles, Covance, PPD, Parexel and Icon. According to Jon Meyer, Principal at Life Science Strategy Group, and author of the report, “The data are clear – many sponsors are satisfied with their existing CROs for clinical development services, but there is a segment expecting or considering shifting to a larger CRO.”

Feedback the OutsourcePharma Advisory Board members goes on to detail recent and expected changes in RFP characteristics including RFP scope/complexity, size, therapeutic area and other attributes, as well as drivers of RFP change for both preclinical and clinical development services.

To learn more about the new report, please visit

To learn more about The OutsourcePharma Advisory Board, please visit

About Life Science Strategy Group, LLC
Life Science Strategy Group, LLC specializes in strategic consulting, market research engagements and syndicated publications across a variety of therapeutic, technology and service industries including contract research services, pharmaceutical, biotechnology, medical devices, diagnostics and drug discovery. It provides oversight and administers The OutsourcePharma Advisory Board.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jon Meyer
Visit website